When will tirzepatide be available — and is it already?

The decision most people are actually making

When this question comes up, it usually reflects one of two situations. Either someone has heard about tirzepatide and wants to know whether it exists yet in the UK, or they already know it exists and are trying to work out whether they can access it, on the NHS, privately, or at all.

The honest short answer: the medicine is here. What's still rolling out is who can get it, through which channel, and in what form. Understanding those distinctions is worth a few minutes, because the decision you face depends almost entirely on which situation applies to you.

One misconception worth setting aside gently: some people assume tirzepatide is still awaiting approval in the UK, perhaps because they've seen US coverage of "Zepbound" (the US brand name for the same molecule). Zepbound doesn't exist as a UK product. In the UK, tirzepatide is Mounjaro, and it has been authorised and actively dispensed here for over two years. The pipeline question, then, isn't about the injection, it's about the oral form and the NHS rollout.

Where the NHS rollout stands right now

NICE recommended tirzepatide for NHS use in December 2024, under technology appraisal TA1026. The recommendation covers adults with a BMI of 35 or above alongside at least one qualifying weight-related condition, with lower BMI thresholds for some ethnic backgrounds. NHS England then set out a phased commissioning schedule, because the service doesn't have the capacity to absorb millions of eligible patients at once.

The first cohort became eligible in June 2025: adults with a BMI of 40 or above and four or more of five specified conditions (high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes). A second cohort (BMI 35 to 39.9 with four or more conditions) was activated in June 2026. A further expansion is expected around March 2027. Prescribing under the 2026 GP contract is also now possible in participating practices, though take-up varies considerably by area.

In Scotland, Wales and Northern Ireland, access thresholds differ. If your situation is nation-specific, it's worth checking with your GP surgery directly, as commissioning varies.

The key practical point: meeting the NICE BMI and comorbidity criteria doesn't guarantee an NHS prescription this year. Wraparound diet and activity support is a requirement, and waiting times for specialist weight management services remain long in most areas.

Private access, the route that exists now

For people who don't meet the NHS criteria, or who'd rather not wait, a private prescription from a regulated UK pharmacy is the legal alternative. The process involves a clinical consultation (a real prescriber reviews your health history, current medicines, weight, and any relevant conditions) and, if approved, treatment can begin quickly.

At nume, every consultation is personally reviewed the same day by a GPhC-registered Independent Prescriber. There's no algorithm making that call. Identity and weight are verified on video before any prescription is issued, and your GP is notified in line with GPhC guidance. Orders placed before 12pm on a working day are dispatched the same day once clinically approved, arriving with DPD the next working day in plain packaging.

On the cost side, private tirzepatide pricing varies by dose and provider. Since Eli Lilly raised UK list prices in September 2025, the higher doses have seen significant increases, worth factoring in from the start. One transparent price at nume covers consultation, prescription, medicine and delivery, with no subscription or auto-renewal.

You can verify any online pharmacy on the GPhC's public register before handing over personal or medical information. You should.

The oral form, when might tirzepatide tablets become available?

This is the part of the question where genuine uncertainty remains. An injectable once-weekly pen is how tirzepatide is currently delivered. There is no oral tirzepatide with UK marketing authorisation at the time of writing. Eli Lilly has been developing an oral version and phase 3 trial data have been reported, but regulatory submission and MHRA review take time after that.

For context, it's worth knowing that oral semaglutide did reach UK approval in June 2026, the MHRA licensed the Wegovy tablet for weight management, making it the first oral GLP-1 medicine authorised in the UK for this purpose. That approval gives a sense of how the regulatory pathway works; it doesn't predict the timeline for tirzepatide, and if you're curious about when a generic version of tirzepatide might become available, that's a separate question with its own timeline worth understanding. If you want to explore whether oral tirzepatide is now available, that page carries the most current picture.

The broader tirzepatide overview covers the mechanism, the evidence and the UK licence in detail, useful background whether you're deciding about treatment now or keeping an eye on what's coming. When you're ready to take the next step, you're welcome to speak to our prescribers about whether you're clinically suitable for treatment today.